Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene reports results from phase III POSTURE Study Evaluating Oral OTEZLA in Ankylosing Spondylitis


Wednesday, 9 Jul 2014 07:00am EDT 

Celgene Corp:Declares results of its phase III POSTURE study evaluating OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with active ankylosing spondylitis.OTEZLA arms did not achieve statistical improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS (Assessment of SpondyloArthritis international Society) 20 response at week 16.Evaluation of the efficacy results is ongoing. 

Company Quote

118.71
2.62 +2.26%
24 Apr 2015